Health Research, Inc.

Arup Bhattacharya

Yun Li

Yuesheng Zhang

Youcef M Rustum

Lu Yang

Karoly Toth

Richard Mazurchuk

Harry K Slocum

Li Tang

Joseph D Paonessa

Rami G Azrak

Feng Geng

Sreenivasulu Chintala

Yi Ding

Mukund Seshadri

Provided are compositions and methods for prophylaxis and/or therapy of ErbB1-positive cancer. The compositions include pharmaceutical preparations that contain isolated or recombinant or modified peptidase D (PEPD) proteins. The methods include prophylaxis and/or therapy of ErbB1-positive cancer by administering a PEPD to an individual who has or is at risk for developing ErbB1-positive cancer.

Method for prophylaxis or treatment of erbb1 positive cancers using a variant peptidase d with reduced activity

Provided is a composition that contains a mixture of broccoli seed and mustard seed. Before mixing the broccoli seed with the mustard seed, the broccoli seed is subjected to baking and a pressurized heat treatment. The broccoli seed is baked at a temperature of at least 200 degrees Fahrenheit for at least 60 minutes, and is subjected to a pressurized heat treatment of at least 200 degrees Fahrenheit at a pressure of at least 10 pounds/square inch for at least 5 minutes. Also provided is a method for therapy and/or prophylaxis of bladder cancer in an individual. The method entails administering orally to the individual a composition that contains an isothiocyanate (ITC) or a derivative thereof such that the administration inhibits the growth and/or recurrence of bladder cancer. Nutraceutical compositions are also provided.

Method for delivery and use of isothiocyanates for prophylaxis and/or therapy of bladder cancer

This invention provides a method for a method for optimizing the regimen for the administration of chemotherapeutic agents. The method comprises administration of a selenium compound to an individual, monitoring the modulation of tumor vessel maturation (TVM) to identify an optimal time for administration of a chemotherapeutic agent. This invention also provides a method to determine whether or not a tumor is likely to be a responder to chemotherapy. The method comprises administration of a selenium compound to an individual and determining whether or not an increase in TVM is observed. An increased TVM following administration of selenium is an indication that the tumor will likely respond the chemotherapy.

Method for optimizing cancer therapy by monitoring maturation of tumor associated vasculature by selenium

Growing community of inventors

Buffalo, NY, United States of America

Arup Bhattacharya